Left atrial to coronary sinus shunting for treatment of heart failure with mildly reduced or preserved ejection fraction: The ALT FLOW Early Feasibility Study 1 ‐year results
ConclusionsIn patients with heart failure and LVEF>40%, the APTURE shunt demonstrated an acceptable safety profile with significant sustained improvements in haemodynamic and patient-centred outcomes, underscoring the need for further evaluation of the APTURE shunt in a randomized trial. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - April 12, 2024 Category: Cardiology Authors: Marcus A. Urey,
Benjamin Hibbert,
Ulrich Jorde,
Peter Eckman,
Trevor Simard,
Marino Labinaz,
Babak Nazer,
Mark Wiley,
Bhanu Gupta,
Andrew Sauer,
Hirak Shah,
Paul Sorajja,
Andres M. Pineda,
Emil Missov,
Ehtisham Mahmud,
Rami Kahwash,
Scott Tags: Research Article Source Type: research
Multimorbidity in the era of increasing life expectancy and aging population
(Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - April 12, 2024 Category: Cardiology Authors: Nikhil Patel,
Joseph Yeboah Tags: Invited Editorial Source Type: research
Supplement Article
(Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - April 10, 2024 Category: Cardiology Tags: ABSTRACTS Source Type: research
Issue Information
(Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - April 10, 2024 Category: Cardiology Tags: ISSUE INFORMATION Source Type: research
Insulin ‐like growth factor binding protein‐7 concentrations in chronic heart failure: Results from the EMPEROR programme
ConclusionAcross the entire left ventricular EF spectrum in the EMPEROR Programme, concentrations of the senescence-associated biomarker IGFBP7 were associated with higher risk clinical status and predicted adverse cardio-renal outcomes even in models adjusted for conventional biomarkers. Empagliflozin did not significantly affect IGFBP7 levels over time. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - April 9, 2024 Category: Cardiology Authors: Jo ão Pedro Ferreira,
Milton Packer,
Naveed Sattar,
Javed Butler,
Sandra González Maldonado,
Marina Panova‐Noeva,
Mikhail Sumin,
Serge Masson,
Stuart J. Pocock,
Stefan D. Anker,
Faiez Zannad,
James L. Januzzi Tags: Research Article Source Type: research
Effects of sacubitril/valsartan according to polypharmacy status in PARAGON ‐HF
ConclusionsPolypharmacy is very common in patients with HFpEF, and those with polypharmacy have worse clinical status and a higher rate of non-fatal and fatal outcomes. The benefit of sacubitril/valsartan was not diminished in patients taking a larger number of medications at baseline. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - April 8, 2024 Category: Cardiology Authors: Shingo Matsumoto,
Mingming Yang,
Li Shen,
Alasdair Henderson,
Brian L. Claggett,
Akshay S. Desai,
Martin Lefkowitz,
Jean L. Rouleau,
Orly Vardeny,
Michael R. Zile,
Pardeep S. Jhund,
Muthiah Vaduganathan,
Scott D. Solomon,
John J.V. McMurray Tags: Research Article Source Type: research
Comparative effectiveness of sacubitril/valsartan versus angiotensin ‐converting enzyme inhibitors/angiotensin receptor blockers in patients with de novo heart failure with mildly reduced and preserved ejection fraction
(Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - April 8, 2024 Category: Cardiology Authors: Ankeet S. Bhatt,
Muthiah Vaduganathan,
Barada Prasad Jena,
Sylwia Suminska,
Carlos Eid,
Rahul Khairnar,
Gabriella Farries,
Michele Senni Tags: Research Letter Source Type: research
Incidence and predictors of heart failure with reduced and preserved ejection fraction after ST ‐elevation myocardial infarction in the contemporary era of early percutaneous coronary intervention
ConclusionIn the current era of early STEMI reperfusion, still one in 10 patients develops heart failure, with approximately half of the patients with a reduced and half with a mildly reduced or normal LVEF. Predictors for the development of HFrEF were different from HFpEF. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - April 5, 2024 Category: Cardiology Authors: Chris Lenselink,
Kim W.L.M. Ricken,
Hilde E. Groot,
Tijs J. de Bruijne,
Tom Hendriks,
Pim van der Harst,
Adriaan A. Voors,
Erik Lipsic Tags: Research Article Source Type: research
Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction – Results from the EMPULSE trial
ConclusionThe clinical benefit of empagliflozin proved consistent across LVEF categories in the EMPULSE trial. These results support early in-hospital initiation of empagliflozin regardless of LVEF. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - April 4, 2024 Category: Cardiology Authors: Jasper Tromp,
Mikhail N. Kosiborod,
Christiane E. Angermann,
Sean P. Collins,
John R. Teerlink,
Piotr Ponikowski,
Jan Biegus,
Jo ão Pedro Ferreira,
Michael E. Nassif,
Mitchell A. Psotka,
Martina Brueckmann,
Jonathan P Blatchford,
Dominik Steu Tags: Research Article Source Type: research
Congestion patterns in severe tricuspid regurgitation and transcatheter treatment: Insights from a multicentre registry
ConclusionIn this large cohort of invasively characterized patients undergoing TTVI, congestion patterns involving right-sided congestion were associated with low procedural success and higher mortality rates after TTVI. Whether pre-interventional reduction of right-sided congestion can improve outcomes after TTVI should be established in dedicated studies. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - April 4, 2024 Category: Cardiology Authors: Karl ‐Philipp Rommel,
Guillaume Bonnet,
Vera Fortmeier,
Lukas Stolz,
Anne R. Schöber,
Jennifer von Stein,
Mohammad Kassar,
Muhammed Gerçek,
Sebastian Rosch,
Thomas J. Stocker,
Maria I. Körber,
Karl‐Patrik Kresoja,
Tanja K. Rudolph,
Rom Tags: Research Article Source Type: research
Sodium –glucose cotransporter 2 inhibitors and skeletal muscle
(Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - April 2, 2024 Category: Cardiology Authors: Andrew J. Stewart Coats Tags: Invited Editorial Source Type: research
Circulating levels of carbohydrate antigen 125 in chronic heart failure: Useful or futile?
(Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - April 2, 2024 Category: Cardiology Authors: Herminio Morillas,
Julio N úñez,
Pedro Moliner Tags: Invited Editorial Source Type: research
Comorbidities and cardiac resynchronization therapy: Do we talk the talk or should we walk the walk?
(Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - April 2, 2024 Category: Cardiology Authors: Domenico D'Amario,
Renzo Laborante,
Pasquale Santangeli Tags: Invited Editorial Source Type: research
Interatrial shunt therapy in advanced heart failure: Outcomes from the open ‐label cohort of the RELIEVE‐HF trial
ConclusionInteratrial shunting with the Ventura device was safe and resulted in favourable clinical effects in patients with HF, regardless of LVEF. Improvements of left and right ventricular structure and function were consistent with reverse myocardial remodelling. These results would support the potential of this shunt device as a treatment for HF. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - April 2, 2024 Category: Cardiology Authors: Josep Rod és‐Cabau,
JoAnn Lindenfeld,
William T. Abraham,
Michael R. Zile,
Saibal Kar,
Antoni Bayés‐Genís,
Neal Eigler,
Richard Holcomb,
Julio Núñez,
Elizabeth Lee,
Michal Laufer Perl,
Gil Moravsky,
Michael Pfeiffer,
John Boehmer,
J Tags: Research Article Source Type: research
Cost ‐effectiveness of remote haemodynamic monitoring by an implantable pulmonary artery pressure monitoring sensor (CardioMEMS‐HF system) in chronic heart failure in the Netherlands
ConclusionsThe current cost-effectiveness study suggests that remote haemodynamic monitoring with PA-guided therapy on top of standard care is likely to be cost-effective for patients with symptomatic moderate-to-severe HF in the Netherlands. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - April 1, 2024 Category: Cardiology Authors: Hamraz Mokri,
Pascal R.D. Clephas,
Rudolf A. de Boer,
Pieter van Baal,
Jasper J. Brugts,
Maureen P.M.H. Rutten ‐van Mölken Tags: Research Article Source Type: research
